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ABSTRACT: We investigated the efficacy of oral and parenteral Mycobacterium bovis bacille
Calmette-Guerin Danish strain 1331 (BCG) in its ability to protect white-tailed deer (Odocoileus
virginianus) against disease caused by M. bovis infection. Twenty-two white-tailed deer were
divided into four groups. One group (n55) received 109 colony-forming units (cfu) BCG via a
lipid-formulated oral bait; one group (n55) received 109 cfu BCG in culture directly to the
oropharynx, one group (n56) was vaccinated with 106 cfu BCG subcutaneously, and one group
served as a control and received culture media directly to the oropharynx (n56). All animals were
challenged 3 mo after vaccination. Five months postchallenge the animals were examined for
lesions. Results indicate that both oral forms of BCG and parenterally administerd BCG offered
significant protection against M. bovis challenge as compared to controls. This study suggests that
oral BCG vaccination may be a feasible means of controlling bovine tuberculosis in wild white-
tailed deer populations.
Key words: BCG, bovine tuberculosis, Mycobacterium bovis, oral vaccination, vaccine,
white-tailed deer.
INTRODUCTION
Bovine tuberculosis(BTb), caused by
Mycobacterium bovis, poses a serious
continual threat to the health and eco-
nomic well-being of both livestock and
humans worldwide. In the developing
world, one third of the population lacks
effective agricultural and food safety
programs, leaving them at substantial risk
for zoonotic infection by M. bovis (Nelson,
1999). In addition, wildlife reservoirs of
BTb are believed to play a very important
role in the epidemiology of this disease in
many countries. In the United States, a
free-ranging white-tailed deer (Odocoileus
virginianus) population located in north-
eastern Michigan serves as such a reser-
voir (Schmitt et al., 1997; Fitzgerald et al.,
2000; Palmer et al., 1999; 2000; Waters et
al., 2004b).
In 1994 M. bovis was isolated from a
hunter-killed white-tailed deer buck from
northern Michigan. Subsequent surveil-
lance of the free-ranging herd verified an
epidemic presence of the disease. Several
other wild mammalian species in the area
have also been found to be infected or
exposed to M. bovis including cervids and
carnivores (Schmitt et al., 1997; Brunning-
Fann et al., 2001). The self-sustaining
presence of bovine tuberculosis in this
wild deer population, and possibly other
wild populations, poses a significant chal-
lenge to Michigan’s efforts to reestablish
its BTb-free status in domestic livestock.
The implementation of an oral vaccination
program, which would effectively reduce
disease and shedding of M. bovis by deer
and other affected species, would signifi-
cantly aid efforts in eradicating BTb from
Michigan.
We assessed the efficacy of orally
administered M. bovis bacille Calmette-
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Guerin Danish strain 1331 (BCG) in
white-tailed deer against infection with
virulent M. bovis. Mycobacterium bovis
bacille Calmette-Guerin is currently the
only vaccine licensed for use in humans
against tuberculosis (Mycobacterium tu-
berculosis), and there are currently no
accepted vaccination programs available to
livestock. In fact, BCG remains the gold
standard against which all experimental
tuberculosis vaccines are compared, and
despite intense efforts to develop a more
effective vaccine, to date there are no new
commercially available tuberculosis vac-
cines. Our study compared two types of
oral BCG vaccination, as well as parenter-
al BCG vaccination, in their ability to
protect white-tailed deer from disease




Thirty yearling female white-tailed deer were
obtained from four BTb-free deer farms
throughout the state of Iowa, USA, and were
shipped to the USDA/ARS National Animal
Disease Center (NADC) in Ames, Iowa, USA,
in January 2005 and housed in an outdoor pen
facility. Prior to shipment the animals were
socialized as a group on one of the supplying
farms for 3 wk. After delivery to NADC,
animals were acclimated for 4 wk prior to start
of the study. At time of challenge, deer were
transferred to a Biosafety level (BL)-3 animal
building. All deer were housed and cared for
according to the Association for Assessment
and Accreditation for Laboratory Animal Care
International and institutional guidelines. This
study was restricted to using a maximum of 30
animals due to space limitations.
Mycobacterium bovis BCG and M. bovis
challenge strains
Mycobacterium bovis BCG Danish strain
1331 in culture and in lipid-formulated pellets
were prepared at the University of Otago,
Immune Solutions Ltd., as described in
Aldwell et al. (2003a, b). Vaccine doses were
determined using standard enumeration tech-
niques by serial dilution plate counting on
Middlebrook’s 7H11 media (Becton-Dickin-
son, Cockysville, Maryland, USA). Mycobacte-
rium bovis (strain 9839 Ames designation) was
grown to midlog phase on Middlebrook 7H9
broth supplemented with 10% oleic acid-
albumin-dextrose complex (OADC) (Difco,
Detroit, Michigan, USA) plus 0.05% Tween
80. Bacilli were harvested from culture media
by pelleting the cells by centrifugation at 2,000
3 G, washing twice with 1 ml of phosphate-
buffered saline solution and diluting to the
appropriate cell density in 2 ml of PBS. The
challenge dose was determined as described
above for vaccine doses.
Vaccination and challenge of animals
White-tailed deer were orally vaccinated
(n58) with approximately 13109 cfu BCG via
lipid-formulated bait (oral bait group). These
deer were each offered a 1 g, unflavored lipid
pellet inside a piece of fresh apple and allowed
to voluntarily eat the bait and apple so that
they chewed the material before swallowing.
Another group of eight deer were orally
vaccinated with BCG in liquid medium (oral
liquid group). A 1-ml preparation of approx-
imately 1.93108 cfu BCG in 7H9 broth was
administered via 3-ml syringe and a 10 French
25-cm sterile urinary catheter (Self-CathH,
Mentor, Minneapolis, Minnesota, USA). Care
was taken to contact the back of the mouth
with the inoculum in order not to bypass the
pharyngeal lymphoid tissue. Seven deer were
vaccinated subcutaneously in the right caudal
cervical area with a 1-ml preparation of
approximately 3.43106 cfu BCG (parenteral
group). Seven deer received 1 ml 7H9 broth
orally directly into the back of the mouth via
syringe and catheter and served as the control
group. Control and vaccinated deer were
housed together in an outdoor paddock until
challenge in an indoor BL3 facility.
At 12 wk post-vaccination, all animals were
anesthetized with an intramuscular (IM)
injection of ketamine hydrochloride (6 mg/
kg) and xylazine (2 mg/kg), moved into a BL3
facility also at NADC, and immediately
challenged with a total of 228 cfu M. bovis
strain 9839 directly into the palatine tonsillar
crypts (114 cfu/tonsil) via pipette, the dose
being divided between the two tonsils. Oral
liquid and parenteral doses of BCG and
challenge dose of M. bovis were retrospec-
tively determined via culture as described
above. The oral bait dose, as estimated from
culture of bacilli prior to lipid formulation, was
approximately 9.23108 cfu.
Mononuclear cell culture
Whole blood was collected by jugular
venipuncture. Peripheral blood mononuclear
cells (PBMCs) were obtained from whole
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blood collected in 60-cc syringes containing
5 ml 2X acid citrate dextrose. PBMCs were
isolated from buffy coat fractions using a
Ficoll-Hypaque (Histopaque-1083, Sigma, St.
Louis, Missouri, USA) technique followed by a
lyse and restore step as described (Waters et
al., 2004a). The PBMCs were resuspended in
supplemented RPMI 1640 (Sigma) and count-
ed. The RPMI 1640 was supplemented with
25 mM N-(2-hydroxyethyl) piperazine-N9-
(2-ethanesulfonic acid) (HEPES) buffer,
100 units/ml penicillin, 0.1 mg/ml streptomy-
cin, 50 mM 2-mercaptoethanol (Sigma), and
10% (v/v) fetal bovine sera (FBS; National
Veterinary Services Laboratory [NVSL],
Ames, Iowa, USA).
Lymphocyte blastogenesis
Lymphocyte blastogenesis assays were per-
formed on days 0, 28, and 83 postvaccination.
Mononuclear cells (53105 cells) were added
to wells of 96-well round-bottom microtiter
plates (Falcon, Becton-Dickinson, Lincoln
Park, New Jersey, USA). Wells contained
medium plus 10 mg/ml M. bovis purified
protein derivative (PPDb, Prionics AG,
Schlieren, Switzerland), 10 mg/ml Mycobacte-
rium avium PPD (PPDa, Prionics AG), 10 mg/
ml rESAT6:CFP10 (E:C, Waters et al.,
2004a), 1 mg/ml pokeweed mitogen (PWM,
Sigma), or medium alone (no stimulation).
Each antigen treatment was run in triplicate.
Cells were incubated for 6 days at 37 C in 5%
CO2 in air, at which time each well was
pulsed with 0.5 mCi methyl-[3H]thymidine
(Amersham Life Science, Arlington Heights,
Illinois, USA) in 50 ml RPMI. Then PBMCs
were incubated for another 24 hr and
harvested onto fiber filters with a 96-well
plate harvester (EG&G Wallace, Gaithers-
burg, Maryland, USA), and the radioactivity
levels measured by liquid scintillation count-
ing. Data are presented as stimulation indices
(SI) where
SI~
Mean counts=min (antigen or mitogen stimulated cultures)
Mean counts=min (nonstimulated cultures)
:
Interferon-c enzyme-linked immunosorbent assay
Interferon-c (IFN- c) responses to myco-
bacterial antigens were measured at 277, 0,
28, 49, and 83 days post-vaccination, and at 13,
52, 88, and 119 days post-challenge (98, 137,
173, and 204 days post-vaccination, respec-
tively) using a commercial enzyme-linked
immunosorbent assay (ELISA) kit (Cervi-
gamTM, Prionics AG) modified as described
in Palmer et al. (2004b) to determine inter-
feron production. Briefly, heparinized whole
blood was collected by jugular venipuncture,
of which 1.5 ml was added to 24-well tissue
culture plates (Falcon, Becton-Dickinson,
Lincoln Park, New Jersey, USA). Treatments
administered included PBS (no stimulation),
20 mg/ml PPDb, 20 mg/ml PPDa, 20 mg/ml
PWM, or 10 mg/ml E:C. Plates were incubated
for 48 hr at 37 C in a humidified chamber with
5% CO2. Samples were centrifuged at 400 3
G, and the plasma supernatants harvested and
stored at 280 C until analysis using the
CervigamTM ELISA according to the manu-
facturer’s instructions. Optical density was
measured at 450 nm using an automated
ELISA microplate reader (Molecular Devices,
Menlo Park, California, USA). Concentrations
(ng/ml) of IFN-c in test samples were
determined by comparing absorbances of test
samples with absorbances of standards within
a linear curve fit (Instat 2.0, GraphPad
Software Inc., San Diego, California, USA).
The IFN-c data (ng/ml) used for statistical
analysis were derived from calculating the
differences between response to antigen and
response to no stimulation (PBS) (antigen
stimulation (ng/ml)2no stimulation (ng/ml).
Post-mortem examination
Twenty weeks post-challenge, the deer were
anesthetized with ketamine hydrochloride
(6 mg/kg) and xylazine (2 mg/kg) and eutha-
nized by intravenous administration of sodium
pentobarbital (SleepawayH, Fort Dodge, Iowa,
USA). Tissues collected for gross pathology,
histopathology, culture, and polymerase chain
reaction (PCR) were palatine tonsils, mandib-
ular lymph nodes (LNs), parotid LNs, medial
retropharyngeal LNs, right prescapular LN,
tracheobronchial LN, mediastinal LNs, right
cranial lung lobe, liver, hepatic LN, and
mesenteric LNs. In the case of bilateral LNs,
excepting the prescapular LNs, portions of
both right and left LNs were collected for both
culture and histopathology. All lung lobes
were carefully examined for lesions, and each
was weighed individually for comparison with
those of the other deer in the study. A scoring
system based on number and extent of gross
lesions was applied to all LNs collected and all
lung lobes for statistical comparison (adapted
from Vordermeier et al., 2002). For the lung
lobes scoring was as follows: a score of ‘‘no
lesions’’ meant there were no gross lesions
detected. A score of ‘‘mild’’ represented
tissues that contained any lesions fewer than
or equal to five gross lesions of less than
10 mm in diameter. A score of ‘‘severe’’ was
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assigned to tissues with greater than or equal
to six gross lesions of less than 10 mm in
diameter or any lesions larger than 10 mm in
diameter. For the LNs scoring was as follows:
a score of ‘‘no lesions’’ meant there were no
gross lesions detected. A score of ‘‘mild’’
represented tissues that contained one small
focus 1–2 mm in diameter. A score of ‘‘severe’’
was assigned to tissues with several small foci
or extensive necrosis. All tissues for culture
and PCR were stored in whirlpak bags at
280 C until testing. Tissues for histopathology
were fixed in neutral-buffered 10% formalin
and processed by routine paraffin embedment
techniques. Sections were cut 5-mm thick,
stained with hematoxylin and eosin, and
examined under light microscopy. Sections
containing microscopic lesions compatible
with tuberculosis were subsequently stained
with Ziehl-Neelsen for identification of acid-
fast organisms. A scoring system was applied to
all tissues collected for histopathology based
on the number and extent of microscopic
granulomatous lesions and was conducted as
follows: a score of ‘‘no lesions’’ meant there
were no granulomatous lesions detected; a
score of ‘‘mild’’ represented tissues that had
granulomas containing macrophages, giant
cells, lymphocytes, and neutrophils, but had
incomplete encapsulation and minimal to no
necrosis present; a score of ‘‘severe’’ was given
to any granulomas that displayed encapsula-
tion, caseous necrosis, and mineralization.
Tissue culture and polymerase chain reaction
We selected right cranial lung lobe, medi-
astinal LN, and medial retropharyngeal LN for
quantitative culture. Tonsil and mesenteric
LNs were selected for general culture. In a
Class 3 biosafety cabinet, a small piece of each
tissue was removed and stored at 280 C for
fresh tissue PCR analysis. All tissues were then
homogenized using a blender (Oster, Shelton,
Connecticut, USA) with 50 ml (LN) or 100 ml
(lung) phenol red broth (NVSL). A 7.5-ml
aliquot was removed and the remaining
sample stored at 280 C for PCR analysis.
The aliquot was then subjected to NaOH
decontamination as follows. Five milliliters of
0.5 M NaOH was added to the 7.5-ml aliquot
and allowed to incubate for 10 min. Then 10 N
HCl was added dropwise until a yellow color
was obtained followed by a dropwise addition
of 1.0 N NaOH until a dusty rose color was
achieved. Samples for general culture were
centrifuged at 3,000 3 G for 15 min. The
supernatant was discarded, and the remaining
sediment was used to inoculate three tubes of
7H10 media and three tubes of 7H11 media
(NVSL). Samples for quantitative culture were
vortexed at high speed for 5 sec and serial-
ly diluted at 1:10 dilutions in PBS out to 1026,
vortexing for 5 sec between each dilution. One
hundred microliters of each dilution was used
to inoculate 7H11 agar plates (NVSL). The
undiluted sample was used to inoculate one
tube of 7H10 media. All cultures were placed
in an incubator at 37 C. Plates were kept in
plastic bags to prevent the agar from drying
out. Samples were checked every 30 days, and
final counts/assessments were made at
60 days.
Samples that produced growth on 7H10 and
7H11 media and considered suspect for
Mycobacterium spp. were picked and stored
in 1 ml phosphate buffered saline at 280 C
for follow-up PCR to confirm or rule out the
presence of M. bovis. Extraction of DNA from
cell culture samples was performed using the
BioRad InstaGeneTMmatrix (Bio-Rad Labora-
tories, Hercules, California, USA) according to
the manufacturer’s instructions with the fol-
lowing modifications: Briefly, each sample was
vortexed, after which 200 ml of cell homoge-
nized sample was transferred into a bead
beater tube (Sarstedt Inc., Newton, North
Carolina, USA) containing 0.5 g of 0.5-mm
zirconium/silica beads (Biospec Products Inc.,
Bartlesville, Oklahoma, USA). Samples were
bead beated using the MBB-8 Mini Bead
Beater (Biospec Products) for 2 cycles
(4,500 rpm) of 10 sec. After a quick spin,
50 ml of bead-beated cells were transferred to
a new tube, to which 200 ml of Instagene
Chelex matrix was added. Next, 14.2 ml of
proteinase K (Amresco Inc., Solon, Ohio,
USA; 20 mg/ml) was added to each sample,
which, after vortexing, was then incubated at
60 C for 30 min. The proteinase K was
inactivated by heating the samples to 100 C
for 10 min. Finally, the samples were centri-
fuged at 11,000 3 G for 10 min, and the
resulting supernatants containing DNA were
saved. For the purposes of PCR, dilutions
were made of the DNA samples ranging from
1:10 to 1:10,000 depending on extent of
turbidity. For every extraction, one tube
containing 200 ml of PBS was included halfway
between the total sample size and at the end of
the extraction samples to serve as appropriate
negative extraction controls.
The samples were then analyzed for M.
tuberculosis complex DNA using a PCR
targeting the IS6110 regions of M. tuberculosis
complex (IS6110 PCR). The IS6110 PCR was
performed using a PTC-100 MJ Thermalycler
(MJ Research Inc., Waltham, Massachusetts,
USA) for 50 cycles. The primers used in the
IS6110 PCR were as follows: forward primer
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(59CTCGTCCAGCGCCGCTTCGG39) and
reverse primer (39CCTGCGAGCGTAGGC
GTCGG59) (Operon Biotechnologies, Inc.,
Huntsville, Alabama, USA). Each IS6110PCR
reaction (25 mL) occurred in a 0.65 mL PCR
tube (Sorenson BioScience Inc., Salt Lake
City, Utah, USA) and consisted of 1X Gen-
eAmp Buffer II, 1.5 mM MgCl (Applied
Biosystems, Foster City, California, USA),
2.5 mM of each deoxynucleoside triphosphate
(Roche Applied Science, Indianapolis, Indi-
ana, USA), 0.4 mM of each primer, 1.875 units
of AmpliTaq Gold Polymerase (Applied Bio-
systems), 10 mL template, and 6.625 mL PCR-
grade water (Hyclone, Logan, Utah, USA)
covered with a 30 mL layer of Chill-Out wax
buffer (Bio-Rad Laboratories). An amplifica-
tion profile of 1) 94 C for 10 min, 2) 94 C for
45 sec, 3) slope 222 degrees at 1 degree C/
1 sec, 4) 72 C for 2.25 min, 5) slope +22 de-
grees at 1.5 degrees C/1 sec, 6) repeat 2–5 for
49 cycles, and 7) 72 C for 2.25 min was
followed by a final extension of 72 C for
10 min.
A positive control (purified M. bovis DNA at
0.5–5 fg/mL) and a negative control (water)
were included in every experiment. Following
the amplification protocol, 10 ml of the ampli-
fication reactions were size fractionated
through 2.5% agarose (Amresco, Inc.) gels in
1X TAE buffer (40 mM Tris acetate, 1 mM
EDTA) (Amresco, Inc.). Gels were stained in
0.001 mg/ml ethidium bromide (Amresco,
Inc.) for 15 min, and products were then
visualized using the BioRad Gel Doc EQ
System (Bio-Rad Laboratories) UV transillu-
minator. Product size was 322 base pairs.
Medial retropharyngeal LN, mediastinal
LN, and right cranial lung lobe–derived fresh
and homogenized tissues were also directly
tested for M. tuberculosis complex by PCR.
Frozen homogenates were placed at 4 C
overnight to thaw. In a class 2 biosafety
cabinet, approximately 1.3 ml homogenate
was removed from the bottom of the 50-ml
polypropylene centrifuge tube and transferred
to a 2-ml polypropylene centrifuge tube.
Samples were centrifuged for 10 min at
11,000 3 G. Saving the resultant phenol broth
supernatant in a new tube, 100 mg of the
tissue was weighed out and placed into a 2-ml
bead beater tube containing 2.5 g of 2.5 mm
and 0.5 g of 0.5 mm zirconia/silica beads, to
which 100 ml of the supernatant was returned.
For every nine samples, a bead beater tube
was filled with 200 ml PBS to serve as negative
control. All tubes were quick spun and placed
in a heat block for 10 min at 100 C. The
samples were allowed to cool for 10 min.
Tubes were then bead beated for three cycles
(4,500 rpm) of 30 sec. Samples were cooled in
an ice block in between cycles to avoid
overheating. At this point samples were
considered safe to handle outside the biosafety
cabinet. DNA extraction was then accom-
plished using the Fermentas Genomic DNA
Purification KitH according to manufacturer’s
instructions (Fermentas Life Sciences, Han-
over, Maryland, USA). Following the manu-
facturer’s recommended DNA ethanol
(ETOH)/salt precipitation, one Breath-Ea-
sierH tube membrane (ISC Bioexpress, Kays-
ville, Utah, USA) was placed over each open
tube to avoid cross-contamination and allow
for proper ETOH evaporation while incubat-
ing at 65 C under a still-air hood. DNA
samples of the homogenized tissue were
rehydrated in 100 ml of TE buffer (10 mM
Tris, 1 mM EDTA) (Amresco Inc.) and
diluted to 1:60 and 1:80 in PCR-grade water
for PCR.
In a class 2 biosafety cabinet, 100 mg of
fresh frozen tissue was weighed out from each
sample for DNA extraction. Tissues were
minced and placed in bead beater tubes,
containing 2.5 g of 2.5 mm and 0.5 g of
0.5 mm zirconia/silica beads, to which 100 ml
of TE buffer was added. Tissues underwent
bead beating homogenization with two pulses
of 30 sec at 4,500 rpm. Samples were cooled
in an ice block in between cycles to avoid
overheating. The Epicentre MasterPureTM
DNA Purification Kit was used according to
the manufacturer’s instructions with some
modifications (Epicentre Biotechnologies, Ma-
dison, Wisconsin, USA). Briefly, samples were
quick spun, and 500 ml of T and C Lysis
Solution with 0.675 mg/ml proteinase K was
added to each sample. Samples were incubat-
ed for 60 min at 56 C and again for 10 min at
100 C to inactivate the proteinase K and
render any remaining M. bovis nonviable.
After the samples cooled, 250 ml of MPC
Protein Precipitation Reagent was added, and
samples were centrifuged at 11,000 3 G for
10 min at 4 C. The supernatant was then
treated with 750 ml of 100% isopropanol and
centrifuged for 15 min at 11,000 3 G at 4 C.
The isopropanol was discarded, and the pellet
was washed two times with 75% ETOH. Any
remaining ETOH was allowed to evaporate by
placing a Breath-EasierH tube membrane over
each open tube as described above. DNA
samples of the fresh tissue were rehydrated in
100 ml of TE buffer and diluted to 1:60 and
1:80 for IS6110 PCR.
DNA from fresh and homogenized tissues
underwent PCR analysis as described above.
Any DNA samples deemed positive were
subjected to two repeat PCR analyses, and
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corresponding tissue samples were subjected
to one additional extraction and PCR analysis
to confirm presence of M. bovis. Unlike
culture, these assays do not reflect the viability
of the mycobacteria, but serve as a sensitive
method to test for evidence of infection at
some time during the experiment.
Statistical analysis
Fisher’s Exact Test (433; one-sided) was
used to compare all groups based on number
of animals with gross lesions (none, mild, and
severe) and microscopic lesions (none, mild,
and severe) (Samuels and Witmer, 1999) (Proc
FREQ; SAS 9.1, SAS Institute, Cary, North
Carolina, USA). If an association existed,
Fisher’s Exact Test (232; one-sided) was
again used to compare the number of animals
with lesions within each vaccine group to the
number of animals with lesions within the
control group or to each other based on no
lesions versus lesions (mild and severe com-
bined). Culture and PCR results were com-
pared in the same manner (Fisher’s Exact
Test; 232; one-sided) in order to determine
differences in number of culture/PCR positive
animals among groups. As this was a resource-
intensive pilot study that was limited to a small
number of animals, statistical priority was
placed on minimizing the chance of type 2
error in order to detect differences if they
were biologically valid. It was determined that
using 8 animals per group, at an alpha level of
0.1, the test would have a power of 0.8 in
detecting a difference when the proportion of
animals without lesions in the vaccine groups
exceeded the proportion of animals without
lesions in the control group by 0.5 (SAS
Institute, 2006). Therefore, differences deter-
mined by the one-sided Fisher’s Exact Test to
have P #0.1 were considered significant.
We modeled IFN-c and lymphocyte blasto-
genesis response variables as functions of
treatment group, time point, and group3time
point interaction. We coupled this fixed-
effects model structure with three alternative
covariance structures to account for random
effects of individual deer, effects of repeated
measures within individuals, and unequal
variances among treatment groups using the
GLIMMIX procedure of SAS (Littell et al.,
2006; SAS Institute 2006). The most general
covariance structure estimated separate vari-
ance components and autoregressive correla-
tion coefficients by treatment group. Models
with reduced covariance structures included
one model estimating a common variance
component (random effect of individuals)
and a common autoregressive correlation
among treatment groups, and one model
estimating a common variance component
(i.e., no treatment-group covariance effect,
no repeated measures effect). We used an
information theoretic approach to select the
most parsimonious form of covariance struc-
ture for each response variable (Burnham and
Anderson, 2002; Littell et al., 2006). For the




Because of illnesses and injuries, eight
animals were removed at various times
throughout the study. Twenty-two animals
remained in the study at the time of post-
mortem examination. Of these 22 animals,
five were in the oral bait group, five were
in the oral liquid group, six were in the
parenteral group, and six were in the
control group.
IFN-c and lymphocyte proliferative responses to
mycobacterial antigens
Overall there was no detectable inter-
action between group and sampling time
regarding IFN-c responses to PPDb or
E:C (P50.25 and 0.39, respectively; data
not shown). There was a significant
interaction detected regarding IFN-c re-
sponses to PPDa, although this interaction
is based on responses obtained at only one
time point (52 days post-challenge;
137 days post-vaccination; data not
shown). Least squares means estimates
of vaccinates were compared to those of
the control group as well. At 28 days post-
vaccination and at 13 days post-challenge
(98 days post-vaccination) the parenteral
group produced significantly greater levels
of response to PPDb relative to the
control group (P50.09 and P50.057,
respectively). At 52 days post-challenge
(137 days post-vaccination) the parenteral
group exhibited increased reactivity to
PPDa in relation to the control group
(P50.062), whereas the oral group exhib-
ited decreased reactivity to PPDa
(P50.0025). The control group showed
greater reactivity to PPDb and E:C than
252 JOURNAL OF WILDLIFE DISEASES, VOL. 44, NO. 2, APRIL 2008
all three vaccine groups at 52 days post-
challenge (P,0.096) (data not shown).
There were no detectable differences in
lymphocyte blastogenic responses to any
of the M. bovis antigens after vaccination
between vaccine groups and the control
group individually or over time (P$0.57;
data not shown).
Post-mortem examination
When present, gross or microscopic
lesions consistent with tuberculous lesions
were found in the right cranial lung lobe
and mediastinal LNs. Lesions were not
consistently observed in any other tissues,
including medial retropharyngeal LNs,
although they were present. Therefore,
only the right cranial lung lobe and
mediastinal LN were suitable for statistical
analysis.
The number of animals sustaining gross
lesions in the right cranial lung lobe and
mediastinal LNs in the vaccine groups was
significantly lower than in the control
group (oral bait—0/5; oral liquid—1/5;
parenteral—1/6; control—6/6 for cranial
lung lobe; oral bait—0/5; oral liquid—0/5;
parenteral—1/6; control—6/6 for medias-
tinal LN; P,0.02) (Table 1). No differ-
ences could be detected among the
vaccine groups regarding the number of
lesions in either right cranial lung lobe or
mediastinal LN (P51.0).
The numbers of animals with micro-
scopic lesions observed in the right cranial
lung lobe and mediastinal LN of the oral
liquid and oral bait groups were signifi-
cantly lower than in the control group
(oral bait—0/5, oral liquid—0/5, control—
6/6 for cranial lung lobe; oral bait—0/5,
oral liquid—0/5, control—6/6 for medias-
tinal LN; P50.002). In the parenteral
group, there were fewer animals having
histologic lesions in the right cranial lung
lobe compared to the control group
(parenteral—1/6, control—6/6; P50.03).
TABLE 1. Microscopic lesions in the right cranial lung lobe and mediastinal lymph nodes of deer vaccinated
with M. bovis BCG Danish strain 1331 via oral and parenteral routes versus deer vaccinated with medium alone.a
Tissueb
Vaccine group
Oral liquid Oral bait Parenteral Controlc
MLNs Culture pos/total 0/5 0/5 0/6 4/6*
(Mean cfu/g)d NA NA NA (5.0861.6) (n53)
PCR pos/total 0/4 0/5 0/6 4/6*
Lesionse pos/total 0/5 0/5 3/5{ 6/6{
RCL Culture pos/total 0/5 0/5 0/6 3/6
(Mean cfu/g) NA NA NA (3.4960.16) (n53)
PCR pos/total 0/4 0/5 1/6 6/6*
Lesions pos/total 0/5 0/5 1/6 6/6*
MRLN Culture pos/total 2/5 0/5 1/6 1/6
(Mean cfu/g) 2/4 NA (3.4) (4.61)
PCR pos/total 2/4 0/5 1/6 2/6
Lesions pos/total 2/5 0/5 1/6 1/6
a All deer were challenged with M. bovis strain 9839 3 mo after vaccination. Tissues were collected 5 mo after challenge.
For the right cranial lung lobe, scoring was as follows: None 5 no gross lesions detected; Mild 5 five or fewer gross
lesions of less than 10 mm in diameter; Severe 5 six or more gross lesions of less than 10 mm in diameter or any lesions
larger than 10 mm in diameter. For the mediastinal lymph nodes scoring was as follows: None 5 no gross lesions
detected; Mild 5 small focus 1–2 mm in diameter; Severe 5 several small foci greater or equal to 5 mm or extensive
necrosis.
b MLNs 5 mediastinal lymph nodes; RCL 5 right cranial lung lobe; MRLN 5 medial retropharyngeal lymph node.
c *Significantly different from all three vaccine groups (Fisher’s Exact Test; P#0.1); {significantly different from Oral
Liquid and Oral Bait groups (Fisher’s Exact Test; P,0.1).
d Mean bacterial count reported as log10 cfu/g 6SD.
e Microscopic lesions
NOL ET AL.—EFFICACY OF ORAL AND PARENTERAL BCG IN WHITE-TAILED DEER 253
However, regarding the mediastinal LN,
the parenteral group did not appear to
differ from the control group (parenter-
al—3/5, control—6/6; P50.18), but did
differ from both oral groups, having more
animals with microscopic lesions in that
tissue compared to the other vaccine
groups (P50.08; Tables 2 and 3). No
differences could be detected among the
vaccine groups regarding the number of
microscopic lesions in the right cranial
lung lobe (P50.13). Microscopic lesions in
the medial retropharyngeal LNs were
found in two animals from the oral liquid
group, one animal from the parenteral
group, and one animal from the control
group. Again, these data were not sub-
jected to statistical analysis and are
summarized in Table 3.
Presence of M. tuberculosis complex in tissues
When looking at all five tissues cultured
(right cranial lung, mediastinal LNs,
medial retropharyngeal LNs, tonsil, mes-
enteric LNs), the oral bait and parenteral
groups, but not the oral liquid group, had
significantly fewer culture positive animals
than did the control group in which all six
animals were positive (oral bait—0/5 pos.,
P50.002; parenteral—2/6 pos., P50.03;
oral liquid—3/5 pos., P50.18). No signif-
icant differences were noted among the
vaccine groups (P50.18). When looking at
differences in individual tissues (Table 3),
there were fewer animals in the oral
liquid, oral bait, and parenteral groups
that were culture positive for M. tubercu-
losis complex in the mediastinal LNs than
in the control group (oral liquid—0/5, oral
TABLE 2. Number of deer that are positive for culture, PCR, or microscopic lesions in selected tissues over
total number of animals tested in the treatment group.a
Vaccine group
Right cranial lung lobe Mediastinal lymph nodes
None Mild Severe None Mild Severe
Oral liquid (n55) 5 0 0 5 0 0
Oral bait (n55) 4 1 0 5 0 0
Parenteral (n56) 5 0 1 5 1 0
Control (n56) 0 0 6b 0 0 6b
a All deer were challenged with M. bovis strain 9839, 3 mo after vaccination. Tissues were collected 5 mo after challenge.
None 5 no granulomatous lesions detected; Mild 5 presence of granulomas containing macrophages, giant cells,
lymphocytes, and neutrophils, but having incomplete encapsulation and minimal to no necrosis present; Severe 5
presence of granulomas displaying encapsulation, caseous necrosis, and mineralization.
b Significantly different from all three vaccine groups (Fisher’s Exact Test; P,0.1).
TABLE 3. Gross lesions in the right cranial lung lobe and mediastinal lymph nodes of deer vaccinated with
M. bovis BCG Danish strain 1331 via oral and parenteral routes versus deer vaccinated with medium alone.a
Vaccine group
Right cranial lung lobe Mediastinal lymph nodes
None Mild Severe None Mild Severe
Oral liquid (n55) 5 0 0 5 0 0
Oral bait (n55) 5 0 0 5 0 0
Parenteral (n56) 5 0 1 2 1 2b
Control (n56) 0 0 6c 0 0 6b
a Deer were vaccinated with M. bovis BCG Danish strain 1331 via oral and parenteral routes or received medium alone.
All deer were challenged with M. bovis strain 9839, 3 mo after vaccination. Tissues were collected 5 mo after challenge.
b Significantly different from Oral Liquid and Oral Bait groups (Fisher’s Exact Test; P,0.1).
c Significantly different from all three vaccine groups (Fisher’s Exact Test; P#0.1).
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bait—0/5, parenteral—0/6, control—4/6;
P#0.045). Regarding the right cranial
lung, there were differences, although
not significant differences, detected be-
tween the vaccine groups and the control
group (oral liquid—0/5, oral bait—0/5,
parenteral—0/6, control—3/6; P50.18).
No differences were observed among the
vaccine groups either. No differences
were seen in the medial retropharyngeal
LN cultures (Table 3). Quantitative cul-
ture results supported the above findings
that M. bovis was more readily cultured
out of mediastinal LNs and right cranial
lung lobe collected from unvaccinated
animals than in tissues from vaccinated
animals. These results are reported in
Table 3; however, they were not subjected
to statistical analysis due to small sample
size.
When PCR was applied directly to
tissues and tissue homogenates, we ob-
served similar trends but greater differ-
ences among the groups as compared to
culture regarding presence of M. tubercu-
losis complex in right cranial lung lobe and
mediastinal LNs (Table 3). The number of
animals testing PCR positive for M.
tuberculosis complex in mediastinal LNs
in the three vaccine groups were signifi-
cantly fewer than in the control group
(oral liquid—0/4, oral bait—0/5, parenter-
al—0/6, control—4/6; P#0.008). As well,
there were significantly fewer animals
testing PCR positive in the right cranial
lung lobe in the three vaccine groups than
in the control group (oral liquid—0/4, oral
bait—0/5, parenteral—1/6, control—6/6;
P#0.072). Again there were no differenc-
es noted among the vaccine groups
(P50.28). Culture, PCR, and histopatho-
logic results in the three tissues are
summarized in Table 3.
DISCUSSION
The present study indicates that oral
BCG Danish 1331 is effective in protect-
ing white-tailed deer against disease
caused by experimental M. bovis infection.
Orally vaccinated deer had fewer tuber-
culous lesions, both gross and microscop-
ic, than did control deer 5 mo after
challenge. To the authors’ knowledge, this
is the first study reporting efficacy of oral
BCG in this species in experimental
settings. Waters et al. (2004b) evaluated
cellular immune responses in white-tailed
deer vaccinated subcutaneously with BCG
Pasteur, and demonstrated strong IFN-c
and proliferative responses to PPDb,
suggesting that BCG may be protective
against M. bovis infection in this species.
Challenge with M. bovis was not per-
formed in this study. Miller and others
(1999) orally administered a recombinant
BCG expressing Borrelia burgdorferi Osp
A to white-tailed deer and detected both
cellular and humoral immune response to
M. bovis antigen, evidence that BCG was
taken up via oral route. However, poten-
tial efficacy of the vaccine against M. bovis
infection was not investigated, as the sole
purpose of this study was to test the
feasibility of BCG as an oral delivery
system for nonmycobacterial antigens. In
a New Zealand study investigating BCG
(Pasteur 1173P2) in red deer (Cervus
elaphus), researchers vaccinated animals
directly in the tonsilar crypt (Griffin et al.,
1999). Similar to oral BCG in white-tailed
deer, the New Zealand scientists demon-
strated that one dose of 2.53106 cfu BCG
into the tonsilar crypt of red deer protect-
ed 8 of 10 animals from disease 21 wk
after M. bovis challenge, and 5 of 10
animals were culture negative. Red deer
that were vaccinated subcutaneously with
the same single dose of BCG experienced
comparable protection, also similar to the
white-tailed deer in this study. It should
be noted that this and subsequent studies
also demonstrated that red deer vaccinat-
ed with two subcutaneous doses of BCG
4–8 wk apart fared better than either
subcutaneous or intratonsilar single-dose
groups after challenge (Griffin et al.,
2006).
The results of the present experiment
indicate that white-tailed deer can be
NOL ET AL.—EFFICACY OF ORAL AND PARENTERAL BCG IN WHITE-TAILED DEER 255
vaccinated orally using BCG incorporated
in a lipid-formulated bait. This oral bait
has successfully induced protection
against M. bovis and M. tuberculosis
infection in a number of species, including
laboratory mice (Aldwell et al., 2003),
brushtail possum (Trichosurus vulpecula;
Aldwell et al., 2003a), European badger
(Meles meles; S. Lesellier, pers. comm.),
and domestic cattle (Buddle et al., 2005).
Buddle and others (2005) first demon-
strated that ruminants can be vaccinated
using this method. In their study, calves
fed 109 cfu BCG (Pasteur 1173P2) via oral
bait and challenged 21 wk after vaccina-
tion had significantly lower lung and LN
lesion scores than did nonvaccinated
cattle. The current findings are consistent
with this previous study and suggest that
white-tailed deer are a good candidate for
oral vaccination programs to control bo-
vine tuberculosis in the field.
This study examined the level of pro-
tection provided by oral BCG in white-
tailed deer 5 mo post-challenge. Although
the level of protection was significant
based on analyses of lung and mediastinal
LNs, these data do not suggest that a lack
of lesions equates to sterile immunity. A
few animals still had evidence of infection,
based on histologic lesions or positive
detection of M. bovis in medial retropha-
ryngeal LNs and occasionally in other
tissues as well (data not shown). For this
reason it was important to test tissues in
parallel via histopathology, PCR, and
culture, as culture for Mycobacteria is
quite difficult and is therefore relatively
insensitive as an independent test. It
would be of great interest to evaluate
disease progression, if any, in this species
in subsequent vaccine trials through ex-
tending the time between challenge and
postmortem examination. Griffin and oth-
ers (2006) addressed this question in red
deer and found that animals vaccinated
subcutaneously 8 wk apart remained re-
fractory to disease up to 52 wk, despite the
fact that they harbored low numbers of M.
bovis in their tissues. Animals with stable,
nonprogressive lesions are less likely to
play an active role in disease transmission
(Griffin et al., 2006). Therefore, vaccines
that do not produce universal sterile
immunity but do significantly limit disease
still have great potential to control en-
demic tuberculosis in wildlife.
The predominant sites of mucosal
uptake of oral BCG in ruminants are
currently unknown. It has been shown in
rabbits that mycobacteria can cross the
mucosal barrier through M cells present in
gut-associated lymphoid tissues, namely,
Peyer’s patches (Fujimura, 1986; Tizzard,
2004). In Lagranderie et al. (2000), mice
vaccinated orally with 23109 cfu BCG
transiently harbored BCG in both the
submaxillary glands and Peyer’s patches
immediately post-vaccination. However,
only the periglandular LNs in the sub-
maxillary region maintained high numbers
of bacilli 84 days after administration of
BCG when compared to the mesenteric
LNs, suggesting that primary uptake
occurs in the pharyngeal region, where
nasopharyngeal lymphoid tissues are pre-
sent. In contrast, mice which received the
same dose intragastrically maintained
higher numbers of bacilli in the mesen-
teric LNs. Aldwell and others (2005a,
2006) inoculated mice with 5.13107 cfu
lipid-microencapsulated BCG and found
that the major site of bacterial replication
was the mesenteric LNs, indicating that
the lipid encapsulation reduced uptake in
the pharyngeal region and protected the
attenuated bacillus from destruction in the
stomach. However, Dorer et al. (2007)
showed BCG to be present in cervical and
mesenteric LNs and Peyer’s patches of
mice 8 wk after receiving 1–23107 cfu
lipid-encapsulated BCG. Similar studies in
other species corroborate these findings,
although they all utilize a monogastric
model. It is therefore of vital importance
to investigate the potential impact of the
complex ruminant gastrointestinal system
upon both protected and nonprotected
BCG in future studies.
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Increases in IFN-c production and
proliferation by lymphocytes in the pres-
ence of M. bovis antigens can be used as
indicators that an appropriate cellular
immune response to BCG vaccination
has occurred. In infected deer, however,
robust IFN-c responses can imply the
presence of more severe disease. Thacker
et al. (2006) found that PBMC from
white-tailed deer with severe pathology
due to M. bovis infection had greater IFN-
c mRNA expression to PPDb and E:C
early on in the infection than did animals
with pathology limited to the head LNs.
As infection progressed the IFN-c re-
sponses of the low-pathology group in-
creased to those of the high-pathology
group. Although the deer in this study
responded well to vaccination, we could
not have predicted this based on our IFN-
c or lymphoproliferative data prior to
challenge. We also did not observe im-
portant differences in IFN-c production
between controls and vaccinates after
infection. It is interesting that the group
that received subcutaneous BCG vaccina-
tion displayed a degree of vacillation in
IFN-c responses not seen in any of the
other groups over the course of the study.
Although this may be due to the differ-
ence in the character of the immune
response to BCG and M. bovis by this
group, there may be other factors in-
volved, such as the influence of exposure
to antigens of M. avium. An important
aspect to consider is that, at multiple time
points, samples from up to 20% of the
animals did not show an IFN-c response
to any antigen, based on the Cervigam
ELISA, including the pokeweed mitogen
control. Similar results were reported in a
study by Waters et al. (in press) evaluating
Cervigam as a diagnostic tool in various
deer species, wherein only 44% of white-
tailed deer had responses to PWM, calling
into question the validity of this test for
this species. In addition, the IFN-c and
lymphocyte responses observed in indi-
vidual deer within groups were extremely
variable. It is quite likely that, had our
sample sizes been larger, we would have
obtained data more consistent with those
reported in other studies.
Experiments involving large, highly
stressed species under BL-3 conditions
are typically limited by space and cost.
Power and significance levels need to be
carefully considered prior to carrying out
such a study and analyzing the results.
Vaccine studies with low sample sizes are
particularly susceptible to producing out-
comes that apparently fail to detect
differences between or among treatment
groups when there actually is a treatment
effect. It is therefore justified to increase
the alpha level and hence choose a higher
P value in order to increase the power of
the test and avoid type 2 error that renders
otherwise valuable data meaningless in a
practical sense. The purpose of this pilot
study was to investigate the feasibility of
pursuing further research with oral BCG
in white-tailed deer. Despite the fact that
our numbers were very small, we were still
able to clearly show that BCG does appear
to be effective in protecting deer from
disease.
In conclusion, the use of BCG for oral
vaccination of white-tailed deer shows
great potential in controlling disease
caused by M. bovis infection. Oral vacci-
nation significantly slowed pathologic pro-
gression of disease in our animals over a 5-
mo period and thus is a promising
candidate for use in field. Oral vaccination
of wildlife is a management tool that has
been successfully implemented in Europe
to control rabies in red fox (Vulpes vulpes;
Brochier et al., 1989) and is currently
being used in the United States to manage
the disease in raccoons (Procyon lotor).
Oral BCG vaccination of wildlife reser-
voirs of bovine tuberculosis is being
extensively researched for application in
many countries, including New Zealand,
United Kingdom, Ireland, United States,
and South Africa. Successful mucosal
delivery (intranasal or intraconjunctival)
of BCG to a wild population of brushtail
possums in New Zealand has already been
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demonstrated by Corner et al. (2002). The
results of this study provide strong support
for further research that could ultimately
lead to safe and successful field vaccina-
tion of white-tailed deer and eventual
eradication of bovine tuberculosis in the
United States.
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